by Dr. Kurt Sales, Chief Scientific Officer In the ever-evolving landscape of pharmaceuticals, ad...
Dr. Kurt Sales Presents Groundbreaking Findings at WRIB Conference Recently Dr. Kurt Sales, the C...
by Kurt Sales The rise of Cell and Gene Therapy products is increasingly becoming more prevalent....
支持澳大利亚临床试验的领先生物分析实验室 Agilex Biolabs 在南澳大利亚阿德莱德的 CMAX 临床研究机构五楼建立了首个卫星处理单位，配备了高度专业化的技术人员。
Recent Report Shows Australia Rising to 3rd in Number of Industry-Initiated Phase I Clinical Trials...
作为 Healius 网络的一部分，Agilex Biolabs 公司继续进行全球扩张和企业发展，斯蒂芬-麦金太尔（Stephen McIntyre）被选为公司首席执行官。
On November 21, 2022, Agilex Biolabs was named this year’s winner for the Editor’s Choice Award for “Top company in clinical research-based development” in BioSpectrum Asia Excellence Awards.
支持澳大利亚临床试验的领先生物分析实验室 Agilex Biolabs 在南澳大利亚阿德莱德的 CMAX 临床研究机构五楼建立了首个卫星处理单位，配备了高度专业化的技术人员。
Circulating tumor DNA (ctDNA) is tumor-deriver fragmented DNA which originates either directly from the tumor or from circulating tumor cells.
Immunogenicity assessment of biotherapeutics is a regulatory requirement and key parameter for assessing the safety and efficacy of a drug candidate.
Immunogenicity assessment is a critical safety attribute for biotherapeutics undergoing clinical development.
Dr. Kurt Sales Appointed as Chief Scientific Officer at Agilex Biolabs Kurt Sales as Chief Scient...
"*" indicates required fields
